Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
174 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01226719 | FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only | completed | Phase 2 | 15 | SCRI Development Innovations, LLCOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT00731211 | Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 57 | SCRI Development Innovations, LLCOTHER | 1 | May 20, 2015 | clinicaltrials |
| NCT00892710 | Trial of Poor Performance Status Patients (ToPPS)(ToPPS) | completed | Phase 2 | 172 | SCRI Development Innovations, LLCOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00894504 | Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer | completed | Phase 2 | 71 | SCRI Development Innovations, LLCOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT01343498 | Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors | completed | Phase 1 | 33 | SCRI Development Innovations, LLCOTHER | 1 | May 1, 2015 | clinicaltrials |
| NCT00193310 | Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer | completed | Phase 2 | 250 | SCRI Development Innovations, LLCOTHER | 0 | Mar 18, 2015 | clinicaltrials |
| NCT00193492 | A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 1 | Jan 5, 2015 | clinicaltrials |
| NCT00390611 | Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer | completed | Phase 2 | 85 | SCRI Development Innovations, LLCOTHER | 1 | Dec 22, 2014 | clinicaltrials |
| NCT00455975 | High-dose Bevacizumab in Advanced Renal Carcinoma Patients | completed | Phase 2 | 119 | SCRI Development Innovations, LLCOTHER | 1 | Dec 22, 2014 | clinicaltrials |
| NCT00821886 | Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 1 | Dec 22, 2014 | clinicaltrials |
| NCT00825734 | Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 83 | SCRI Development Innovations, LLCOTHER | 1 | Dec 22, 2014 | clinicaltrials |
| NCT00915603 | Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer | completed | Phase 2 | 113 | SCRI Development Innovations, LLCOTHER | 1 | Dec 22, 2014 | clinicaltrials |
| NCT00759928 | PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors | completed | Phase 1 | 48 | SCRI Development Innovations, LLCOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00193154 | OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 63 | SCRI Development Innovations, LLCOTHER | 1 | Apr 1, 2014 | clinicaltrials |
| NCT01014351 | Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | completed | Phase 2 | 70 | SCRI Development Innovations, LLCOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT00193063 | Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer | completed | Phase 2 | 41 | SCRI Development Innovations, LLCOTHER | 0 | Mar 12, 2014 | clinicaltrials |
| NCT00360360 | Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00876408 | Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer | completed | — | 30 | SCRI Development Innovations, LLCOTHER | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00876382 | Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma | completed | — | 47 | SCRI Development Innovations, LLCOTHER | 1 | Nov 14, 2013 | clinicaltrials |
| NCT00193609 | Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site | completed | Phase 2 | 48 | SCRI Development Innovations, LLCOTHER | 1 | Nov 11, 2013 | clinicaltrials |
| NCT00392392 | Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer | completed | Phase 2 | 29 | SCRI Development Innovations, LLCOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00965861 | SCRI Tissue Testing Registry | terminated | — | 20 | SCRI Development Innovations, LLCOTHER | 1 | Aug 28, 2013 | clinicaltrials |
| NCT00550199 | LBH589 and Gemcitabine in the Treatment of Solid Tumors | terminated | Phase 1 | 17 | SCRI Development Innovations, LLCOTHER | 1 | Aug 19, 2013 | clinicaltrials |
| NCT00284180 | Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer | completed | Phase 2 | 32 | SCRI Development Innovations, LLCOTHER | 1 | Aug 9, 2013 | clinicaltrials |
| NCT00193037 | Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer | completed | Phase 2 | 102 | SCRI Development Innovations, LLCOTHER | 1 | Jul 31, 2013 | clinicaltrials |
| NCT00323739 | Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma | completed | Phase 2 | 80 | SCRI Development Innovations, LLCOTHER | 1 | Jul 26, 2013 | clinicaltrials |
| NCT00193596 | Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site | completed | Phase 3 | 198 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2013 | clinicaltrials |
| NCT00544167 | Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer | completed | N/A | 45 | SCRI Development Innovations, LLCOTHER | 1 | Apr 1, 2013 | clinicaltrials |
| NCT00284154 | Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer | completed | Phase 2 | 51 | SCRI Development Innovations, LLCOTHER | 1 | Mar 13, 2013 | clinicaltrials |
| NCT00540579 | CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas | completed | Phase 1 / Phase 2 | 23 | SCRI Development Innovations, LLCOTHER | 1 | Mar 13, 2013 | clinicaltrials |
| NCT00837031 | Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas | completed | Phase 2 | 72 | SCRI Development Innovations, LLCOTHER | 1 | Mar 13, 2013 | clinicaltrials |
| NCT00536575 | Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 13 | SCRI Development Innovations, LLCOTHER | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00392704 | Treatment of Head & Neck Cancer With Chemotherapy and Radiation | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 1 | Feb 22, 2013 | clinicaltrials |
| NCT00611689 | Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors | completed | Phase 1 | 45 | SCRI Development Innovations, LLCOTHER | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00613145 | Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors | completed | Phase 1 | 32 | SCRI Development Innovations, LLCOTHER | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00193258 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 94 | SCRI Development Innovations, LLCOTHER | 0 | Jan 31, 2013 | clinicaltrials |
| NCT00305942 | Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 61 | SCRI Development Innovations, LLCOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00294190 | Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer | completed | Phase 2 | 38 | SCRI Development Innovations, LLCOTHER | 1 | Dec 10, 2012 | clinicaltrials |
| NCT00193453 | Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 69 | SCRI Development Innovations, LLCOTHER | 1 | Nov 13, 2012 | clinicaltrials |
| NCT00876070 | Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer | completed | — | 198 | SCRI Development Innovations, LLCOTHER | 1 | Nov 21, 2011 | clinicaltrials |
| NCT00193583 | Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors | completed | Phase 1 | 18 | SCRI Development Innovations, LLCOTHER | 1 | May 4, 2011 | clinicaltrials |
| NCT00193011 | Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer | completed | Phase 3 | 150 | SCRI Development Innovations, LLCOTHER | 0 | May 3, 2011 | clinicaltrials |
| NCT00193024 | Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer | terminated | Phase 2 | 90 | SCRI Development Innovations, LLCOTHER | 0 | May 3, 2011 | clinicaltrials |
| NCT00193076 | Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer | completed | Phase 2 | 96 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00193102 | Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer | terminated | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | May 3, 2011 | clinicaltrials |
| NCT00193141 | Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer | completed | Phase 2 | 200 | SCRI Development Innovations, LLCOTHER | 0 | May 3, 2011 | clinicaltrials |
| NCT00193167 | Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00193271 | Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer | completed | Phase 2 | 30 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00193297 | Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma | completed | Phase 2 | 50 | SCRI Development Innovations, LLCOTHER | 0 | May 3, 2011 | clinicaltrials |
| NCT00193336 | Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 0 | May 3, 2011 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials